What are the risks of hepatectomy in a patient with Child-Pugh class C cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 18?

Hepatectomy in Child-Pugh C with MELD 18: Prohibitively High Risk

Hepatectomy is contraindicated in a patient with Child-Pugh class C cirrhosis and MELD score of 18 due to prohibitively high perioperative mortality of 30-50%, and this patient should be evaluated for liver transplantation instead. 1

Risk Stratification

Mortality Risk by Classification Systems

The evidence consistently demonstrates that both Child-Pugh C status and MELD score ≥9 independently predict catastrophic surgical outcomes:

• Child-Pugh C patients: Perioperative mortality ranges from 30-50% after hepatectomy 1
• MELD score ≥9: Associated with 29% perioperative mortality versus 0% mortality in patients with MELD <9 2
• MELD score of 18: Falls well above the safety threshold, with studies showing MELD >8 as an independent predictor of both perioperative mortality and decreased long-term survival 2

The most recent EASL 2025 guidelines 3 explicitly state that Child-Pugh class B is an absolute contraindication to liver resection, making Child-Pugh C even more definitively contraindicated. While some highly selected Child-Pugh B7 patients may be considered for minimally invasive surgery, this does not extend to Child-Pugh C patients.

Specific Risk Factors in This Patient

Your patient has a lethal combination:

1. Decompensated cirrhosis (Child-Pugh C indicates presence of ascites, encephalopathy, severe coagulopathy, hyperbilirubinemia, and/or hypoalbuminemia)
2. Elevated MELD score (18 indicates significant hepatorenal dysfunction with elevated bilirubin, creatinine, and INR)
3. High risk of post-hepatectomy liver failure due to insufficient hepatic reserve

Pathophysiological Basis for Contraindication

The combination of Child-Pugh C and MELD 18 indicates:

• Severe portal hypertension with hepatic vein pressure gradient >10 mmHg 4
• Inadequate functional liver remnant that cannot sustain metabolic demands post-resection
• Impaired synthetic function (coagulopathy, hypoalbuminemia)
• Renal dysfunction contributing to MELD elevation
• High probability of postoperative decompensation with ascites, hepatic encephalopathy, and multiorgan failure

Studies demonstrate that patients with both portal hypertension and elevated bilirubin have <30% 5-year survival regardless of Child-Pugh stage 4.

Alternative Management Strategy

The appropriate treatment pathway for this patient is:

1. Liver transplantation evaluation - This is the potentially optimal therapy for patients with Child-Pugh B or C cirrhosis and HCC, as it addresses both the tumor and underlying liver disease 1

2. Locoregional therapy if transplant-eligible:

   • Transarterial chemoembolization (TACE)
   • Radiofrequency ablation (RFA) for small tumors
   • These serve as bridge therapy to transplantation

3. Systemic therapy if not transplant-eligible:

   • Sorafenib or other approved systemic agents for advanced HCC
   • Palliative care consultation

4. Supportive care only if transplant criteria exceeded - Child-Pugh C patients whose tumors exceed transplant listing criteria should receive supportive care 5

Critical Pitfalls to Avoid

• Do not proceed with hepatectomy based solely on tumor resectability without comprehensive liver function assessment
• Do not rely on Child-Pugh classification alone - incorporate MELD score, portal pressure measurements, and volumetric assessment 3
• Do not delay transplant evaluation - patients with Child-Pugh C may not have another window for transplantation if cirrhosis progresses or HCC recurs after alternative treatments 3
• Avoid emergency surgery - MELD ≥18 in emergency settings carries 36% 90-day mortality even for non-hepatectomy procedures 6

Evidence Quality Note

The most recent and highest-quality evidence comes from the 2025 EASL Clinical Practice Guidelines 3, which represents the current standard of care and explicitly addresses perioperative mortality targets (<3%) that cannot be achieved in Child-Pugh C patients. This is supported by consistent findings across multiple earlier guidelines 1, 4, 5, 7 and validated by research demonstrating zero mortality in MELD <9 patients versus 29% in MELD ≥9 patients 2.